FDA Approves Tucatinib as First-Line Maintenance for Advanced HER2-Positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved tucatinib (Tukysa), in combination with trastuzumab and pertuzumab, for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer. This approval is for patients who have not experienced disease progression after completing induction therapy with trastuzumab, pertuzumab, and a taxane, moving tucatinib into an earlier treatment setting.